Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashish M. Kamat to Its Scientific Board of Advisors
(firmenpresse) -
IMAGIN MEDICAL WELCOMES WORLD-RENOWNED BLADDER CANCER EXPERT DR. ASHISH M. KAMAT TO ITS SCIENTIFIC BOARD OF ADVISORS
Vancouver, B.C. and Boston, MA, April 17, 2019 - Imagin Medical (CSE: IME) (OTCQB: IMEXF) (Frankfurt & Stuttgart Symbol: DPD2) (Imagin or the Company) today announced that Dr. Ashish M. Kamat has joined its Scientific Advisory Board.
Dr. Kamat has been named by Expertscape as the worlds top-rated expert in urinary bladder neoplasms. Dr. Kamat has extensive experience with cystoscopic procedures, has been a principal investigator for multiple oncology and urology clinical studies for both drugs and devices, and has been involved in blue light cystoscopy studies since 2007.
Dr. Kamat is an Endowed Professor of Urologic Oncology and Cancer Research at University of Texas MD Anderson Cancer Center (MDACC); Associate Cancer Center Director, RFHNH in Mumbai, and President of International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). He is Associate Editor for European Urology Oncology, directed the MDACC Urologic Oncology Fellowship from 2005-2016, and is an alumnus of the American Urological Association Leadership Program.
Dr. Kamat received his medical degree at the University of Bombay, Indias Seth G. S. Medical College & King Edward Memorial Hospital and completed a fellowship in Urologic Oncology at the MD Anderson Cancer Center. Dr. Kamat focuses on bladder cancer, immunotherapy and organ sparing therapies. He has led several national and international studies, which have been reported in high impact journals. Dr. Kamat has over 300 publications, is listed in ''Who''s Who in Medicine'' and Best Doctors in America, and has won the Compassionate Doctor Award from patient groups.
The advent of enhanced cystoscopy, especially photodynamic diagnosis, has provided us with a means to better detect, diagnose and treat our patients who have bladder cancer, said Dr. Kamat. The technology being developed by the team at Imagin has the potential to allow this technology to be adopted by many centers which currently are not able to do so.
We are honored to have Dr. Kamat, a worldwide bladder cancer expert, join our Scientific Advisory Board, said Jim Hutchens, Imagins President and CEO. Dr. Kamat has extensive experience with cystoscopy, so his expertise will be invaluable as we progress the development of the Companys i/Blue Imaging System.
I am excited to join Imagins Scientific Board of Advisors and look forward to supporting Imagin as it advances i/Blue to commercialization, said Dr. Kamat.
About Imagin Medical
Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries. The Company believes its first product, the i/BlueTM Imaging System, will dramatically improve surgeons ability to visualize cancerous cells by producing higher-quality images more quickly compared with current methods. Based on advanced optics and light sensors, the i/Blue Imaging System employs patented ultrasensitive imaging technology and offers easy-to-use viewing options for more accurate resection. The Companys initial focus is bladder cancer. Learn more at www.imaginmedical.com.
Forward-Looking Statements
Information set forth in this news release contains forward-looking statements. These statements reflect managements current estimates, beliefs, intentions and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Companys control. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Specifically, there is no assurance the Companys imaging system will work in the manner expected. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information. The CSE has neither approved nor disapproved the information contained herein and does not accept responsibility for the adequacy or accuracy of this news release.
Contacts:
Stephen Kilmer, Investor Relations
Telephone: 647-872-4849
Email: stephen(at)kilmerlucas.com
Jim Hutchens, President & CEO
Telephone: 833-246-2446
-
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
" alt="Millennial Lithium Announces Approximately 100 Percent Increase to 4,200,000 Tonnes in Measured And Indicated Lithium Resources At Pastos Grandes">
" alt="CAMEO TO CHANGE NAME TO CAMEO INDUSTRIES CORP.">
Datum: 17.04.2019 - 08:03 Uhr
Sprache: Deutsch
News-ID 1548618
Anzahl Zeichen: 14749
contact information:
Contact person:
Town:
Wien
Phone:
Kategorie:
Business News
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 628 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Imagin Medical Welcomes World-Renowned Bladder Cancer Expert Dr. Ashish M. Kamat to Its Scientific Board of Advisors
"
steht unter der journalistisch-redaktionellen Verantwortung von
Imagin Medical (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
